title: Finasteride in the treatment of benign prostatic hyperplasia.
abstract: Finasteride is an enzyme inhibitor which blocks the conversion of testosterone by 5 alpha-reductase to dihydrotestosterone, the active androgenic metabolite in the prostate. In a double-blind, placebo-controlled study, 707 patients with moderately symptomatic BPH were treated for 2 years. The study confirmed that treatment significantly improved symptoms, reduced prostate size and increased urine flow rate. Side effects were usually mild. The authors find that finasteride can reverse the natural progression of BPH.
authors.affiliation: Karolinska Hospital Stockholm, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Ekman
authors.forename: J T
authors.initials: JT
authors.lastname: Andersen
authors.forename: H
authors.initials: H
authors.lastname: Wolf
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000302:isolation & purification; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology
chemical_list: D004791:Enzyme Inhibitors; D018120:Finasteride; D017430:Prostate-Specific Antigen